Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 585-589

  Holst, Jan ^a,b   Lindblad, Bengt ^b   Matthíasson, Stefan E ^b   Stjernquist, Ulf ^b   Ezban, Mirella ^c   Østergaard, Per B ^c   Hedner, Ulla ^c  

^a HELSINGBORG HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; TINZAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; STOMACH MUCOSA;

EID: 0029997618     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650326     Document Type: Article

References (37)

1. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-49.
2. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
3. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992, 29: 213-26.
4. Rapaport SI, Rao LVM. The tissue factor pathway; how it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
5. Holst J, Lindblad B, Bergqvist D, Nordfang O, Østergaard PB. Is EPI as antithrombotic agent comparable to LMWH? - A pilot double-dummy experimental study. Thromb Haemost 1991; 6: 951.
6. Holst J, Lindblad B, Bergqvist D, Nordfang O, Østergaard PB, Petersen J, Nielsen G, Hedner U. Antithrombotic effect of recombinant truncated Tissue Factor Pathway Inhibitor (TFPI1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-9.
7. Holst J, Lindblad B, Nordfang O, Østergaard PB, Hedner U. Does the glycosylation influence the experimental antithrombotic effect of two-domain Tissue Factor Pathway Inhibitor? Haemostasis 1996; 26: 23-30.
8. Holst J, Lindblad B, Westerlund G, Bregengaard C, Ezban M, Østergaard PB, Nordfang O, Hedner U. Pharmacokinetics and delayed antithrombotic effect of two-domain non-glycosylated Tissue Factor Pathway Inhibitor (TFPI). Thromb Res (accepted).
9. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that effect their ability to interact and to inhibit factor VII-tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
10. Mersereau WA, Hinchey EJ. Effect of gastric acidity on gastric ulceration induced by hemorrhage in rat, utilizing a gastric chamber technique. Gastroenterology 1973; 64: 1130-5.
11. Whittle BJR, Kaufman GL Jr, Moncada S. Hemostatic mechanism, independent of platelet aggregation, arrest gastric mucosal bleeding. Proc Natl Acad Sci USA 1986; 83: 5683-7.
12. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
13. Petersen JGL, Meyn G, Rasmussen JS, Christiansen L, Petersen J, Bjørn SE, Jonassen I, Nordfang O. Chararacterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisae. J Biol Chem 1993; 268: 13344-51.
14. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
15. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen M, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kiesel W. Recombinant Human Extrinsic Pathway Inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
16. Mätzsch T, Bergqvist D, Hedner U, Østergaard PB. Effects of an enzymaticaliy depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
17. Berstad A, Bang CJ, Talstad I. A new model to assess haemorrhagic potential of various heparin preparations. Acta Chir Scand 1990; 556: 62-7.
18. Broze GJ, Likert K, Higuchi D. Inhibition of Factor VIIa/tissue factor by antithrombin III and tissue factor pathway inhibitor. Blood 1993; 82: 1679-80.
19. Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-7.
20. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood. 1995; 85: 121-9.
21. Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992; 111: 681-7.
22. Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis 1984; 14: 440-4.
23. Warn-Cramer BJ, Maki SL, Rapaport SI. A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunogenetically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb Res 1991; 61: 515-27.
24. Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995; 25: 203-11.
25. Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochem 1991; 30: 10371-6.
26. Haskel EJ, Torr KC, Day KC, Palmier MO, Wun TC, Sobel BE, Abendschein DR. Prevention of reocclusion after thrombolysis with recombinant lipoprotein associated coagulation inhibitor. Circulation 1991; 84: 821-7.
27. Spokas EG, Wun TC. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods 1992; 27: 225-32.
28. Khouri RK, Koudsi B, Kaiding F, Ornberg RL, Wun T-C. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993; 30: 398-404.
29. Arnljots B, Bergqvist D, Dahlbäck B. Inhibition of microarterial thrombosis by activated protein C in a rabbit model. Thromb Haemost 1994; 72: 415-20.
30. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and charactarization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
31. Novotny WF, Brown SG, Girard TJ, Miletich JP, Broze GJ Jr. Plasma LACI antigen in patient samples. Blood 1991; 78: 387-93.
32. Llobet D, Mateo J, Vallvé C, Martinez E. Fontcuberta Borrell M. TFPI deficiency in two siblings with thrombophilia. Thromb Haemost 1995; 73: 945.
33. Holst J, Lindblad B, Wedeberg E, Bergqvist D, Nordfang O, Østergaard PB, Hedner U. Tissue Factor Pathway Inhibitor levels in patients with spontaneous deep vein thrombosis. Thromb Res 1993; 72: 467-70.
34. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenetically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-5.
35. Callander NS, Rao MVL, Nordfang O, Warn-Cramer B, Rapaport SI. Mechanism of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. J Biol Chem 1992; 267: 876-82.
36. Bauer KA, Kass BL, Cate ten H, Bednarek MA, Hawinger JJ, Rosenberg RD Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
37. Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Bio Chem 1989; 264: 4743-6.